Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1700 Owens Street, Suite 205, San Francisco, United States

oaksapollo Jan. 9 at 6:52 PM

$NRIX Was able to sell 10 Feb $25 covered calls today for $0.70. Seems like a great deal with pretty bullish pricing. However, the last time I sold $18 covered calls when the stock was at $10 they actually got exercised. I won't be too upset if it happens again. Still own 97.5% of my position free and clear.

1 · Reply

anachartanalyst Jan. 8 at 1:02 PM

$NRIX https://anachart.com/wp-content/uploads/ana_temp/1767877286_soc-img.jpg

0 · Reply

notreload_ai Jan. 8 at 1:01 PM

$RCUS , $NRIX , $IOBT ... Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects. https://notreload.xyz/morgan-stanley-changes-ratings-on-rcus-nrix-iobt/

0 · Reply

oaksapollo Jan. 7 at 8:59 PM

$NRIX I just read that Amgen paid $840M for a single, preclinical degrader. 😲 If that’s the kind of environment we’re in, Nurix should be worth $3-4B at least.

0 · Reply

garygb Jan. 5 at 8:51 PM

$NRIX This should really run.

1 · Reply

OfficialStocktwitsUser Jan. 1 at 9:27 PM

$NRIX RSI: 41.01, MACD: 0.9586 Vol: 0.91, MA20: 18.95, MA50: 15.63 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

LongTrainRunning Jan. 1 at 1:43 AM

$NRIX Cheers to my fellow longs who held steady during this bumpy year! 2025 brought us a lot of great data and progress. I’m looking forward to an even better 2026. Hopefully, we’ll be closer to 30 this time next year.

0 · Reply

Pika_Capital Dec. 26 at 8:00 PM

$BHVN out for 35% profit. Redeployed proceeds into $NRIX Bhvn full of sh*t.

1 · Reply

IN0V8 Dec. 26 at 4:43 PM

$NRIX Opportunity Truist Securities raises target price to $30 from $23

0 · Reply

RhineReturns Dec. 25 at 9:11 AM

$NRIX The valuation debate now centers on reliability of delivery, as investors weigh durability over pace. The upside case requires evidence, not projection.

1 · Reply

Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside

Jan 12, 2026, 7:00 AM EST - 5 hours ago

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Jan 5, 2026, 7:00 AM EST - 7 days ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 4:27 AM EST - 4 weeks ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Dec 8, 2025, 8:00 AM EST - 5 weeks ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

$Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition$

Dec 6, 2025, 9:30 AM EST - 5 weeks ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 1, 2025, 7:00 AM EST - 6 weeks ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 25, 2025, 7:00 AM EST - 6 weeks ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 2 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 2 months ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 2 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 6:53 PM EDT - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Oct 22, 2025, 7:20 AM EDT - 2 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 2 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 3 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 11, 2025, 8:13 AM EDT - 3 months ago

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Oct 9, 2025, 4:01 PM EDT - 3 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 12, 2025, 9:56 AM EDT - 4 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:43 AM EDT - 4 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 11, 2025, 3:14 AM EDT - 4 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 10, 2025, 9:42 AM EDT - 4 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Jul 13, 2025, 8:30 AM EDT - 6 months ago

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 6 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 6 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 7 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 8 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 8 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 8 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 9 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 9 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 9 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 10 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 10 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 10 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Feb 4, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 1 year ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 6, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

oaksapollo Jan. 9 at 6:52 PM

1 · Reply

anachartanalyst Jan. 8 at 1:02 PM

$NRIX https://anachart.com/wp-content/uploads/ana_temp/1767877286_soc-img.jpg

0 · Reply

notreload_ai Jan. 8 at 1:01 PM

0 · Reply

oaksapollo Jan. 7 at 8:59 PM

$NRIX I just read that Amgen paid $840M for a single, preclinical degrader. 😲 If that’s the kind of environment we’re in, Nurix should be worth $3-4B at least.

0 · Reply

garygb Jan. 5 at 8:51 PM

$NRIX This should really run.

1 · Reply

OfficialStocktwitsUser Jan. 1 at 9:27 PM

0 · Reply

LongTrainRunning Jan. 1 at 1:43 AM

0 · Reply

Pika_Capital Dec. 26 at 8:00 PM

$BHVN out for 35% profit. Redeployed proceeds into $NRIX Bhvn full of sh*t.

1 · Reply

IN0V8 Dec. 26 at 4:43 PM

$NRIX Opportunity Truist Securities raises target price to $30 from $23

0 · Reply

RhineReturns Dec. 25 at 9:11 AM

$NRIX The valuation debate now centers on reliability of delivery, as investors weigh durability over pace. The upside case requires evidence, not projection.

1 · Reply

Ravbcentinal Dec. 19 at 9:24 PM

$NRIX LOTS of the volume Today!

0 · Reply

IN0V8 Dec. 16 at 8:53 PM

$NRIX Opportunity Wells Fargo raises target price to $30 from $21

0 · Reply

degeneratetrader23 Dec. 16 at 4:24 PM

$NRIX gap filled.

1 · Reply

anachartanalyst Dec. 16 at 4:02 PM

$NRIX https://anachart.com/wp-content/uploads/ana_temp/1765900898_soc-img.jpg

0 · Reply

JarvisFlow Dec. 16 at 2:58 PM

Wells Fargo updates rating for Nurix Therapeutics ( $NRIX ) to Overweight, target set at 21 → 30.

0 · Reply

oaksapollo Dec. 16 at 2:50 PM

$NRIX bexo will be approved for CLL/WM but just like NX-1607, will be used by clinicians for a wide variety of things https://www.biorxiv.org/content/biorxiv/early/2025/12/03/2025.12.02.691893.full.pdf

1 · Reply

aletz Dec. 15 at 2:42 PM

$NRIX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk3/ My weekly AI scanner picked NRIX for potential swing idea. I will definitely spend more time studying this ticker, recent price action and momentum is very interesting.

0 · Reply

JFais Dec. 12 at 3:26 PM

$NRIX- nice run up so far to $19

0 · Reply

LongTrainRunning Dec. 10 at 4:18 PM

$NRIX I’m bullish long-tern but I’m betting that we drop significantly between now and EHA in June because we’ll be in a catalyst vacuum without much buyer support. That’s why I sold a good amount on Monday when we jumped on ASH news. I want to buy back between now and EHA. Who wants to guess how low we’ll go during that period and when the low will be? I think we might see $14 in March. If you have a different projection for the next six months let’s hear it.

3 · Reply

JarvisFlow Dec. 10 at 2:40 PM

Mizuho updates rating for Nurix Therapeutics ( $NRIX ) to Outperform, target set at 24 → 30.

0 · Reply

JarvisFlow Dec. 10 at 12:42 PM

HC Wainwright & Co. has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 31.

0 · Reply

JarvisFlow Dec. 9 at 6:52 PM

BTIG has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 30.

0 · Reply

Market Cap	1.48B
Revenue (ttm)	54.55M
Net Income (ttm)	-193.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-354.85%
Debt to Equity Ratio	0.00

Volume	1,425,200
Avg Vol	1,732,074
Day's Range	N/A - N/A
Shares Out	76.88M
Stochastic %K	79%
Beta	1.93
Analysts	Strong Sell
Price Target	$28.89